Drugs / YYD601
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03943992 | Jan 2019 → Jan 2020 | esophagitis | Yooyoung Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YYD601 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03943992 ↗ |
| Known as | Esomeprazole magnesium trihydrate | “Esomeprazole magnesium trihydrate, a substituted benzimidazole.” NCT03943992 ↗ |
| Modality | Small molecule | “a substituted benzimidazole” NCT03943992 ↗ |